Ross R S, Viazov S, Wolters B, Roggendorf M
Institute of Virology, National Reference Centre for Hepatitis C, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
J Virol Methods. 2008 Mar;148(1-2):25-33. doi: 10.1016/j.jviromet.2007.10.012. Epub 2007 Nov 28.
Commercially available assays for typing of hepatitis C virus (HCV) isolates satisfy the current clinical needs. They are, however, limited in their ability to identify the multitude of existing HCV subtypes correctly. Therefore, these kits should only be used cautiously in epidemiological studies and will also not meet future clinical demands which might arise, e.g., from the application of HCV subtype-specific antiviral compounds. In an attempt to overcome the drawbacks of commercial typing procedures based on the analysis of the 5' untranslated region (5' UTR), an approach was developed which relies on CLIP sequencing of an HCV core fragment with automated assignments of types and subtypes via an originally created "core-specific" sequence database. The performance characteristics of the new technique were evaluated in comparison to the Trugene 5' NC Genotyping Kit. The core-based sequencing method could regularly detect HCV isolates of genotypes 1-6 with an analytical sensitivity of 5000 IU/ml. The accuracy of typing results obtained by the Trugene test was 97% (genotypes) and 81% (subtypes). The core-linked approach classified all HCV strains correctly on the level of genotypes and led to an adequate subtype assignment in 96% of all cases. This analytical performance characteristics recorded for the newly devised typing technique was superior to those reported for all commercially available assays, including a most recently released new generation of the line probe assay. Consequently, CLIP sequencing of an HCV core fragment with subsequent automated assignment of types and subtypes can be confidently used in clinical laboratory practice to answer current and also future questions in the context of HCV typing.
用于丙型肝炎病毒(HCV)分离株分型的市售检测方法满足当前临床需求。然而,它们正确识别众多现有HCV亚型的能力有限。因此,这些试剂盒在流行病学研究中应谨慎使用,也无法满足未来可能出现的临床需求,例如来自HCV亚型特异性抗病毒化合物应用所产生的需求。为了克服基于5'非翻译区(5'UTR)分析的商业分型程序的缺点,开发了一种方法,该方法依赖于HCV核心片段的CLIP测序,并通过最初创建的“核心特异性”序列数据库自动分配类型和亚型。与Trugene 5'NC基因分型试剂盒相比,评估了新技术的性能特征。基于核心的测序方法可以常规检测1-6型HCV分离株,分析灵敏度为5000 IU/ml。Trugene检测获得的分型结果准确性为97%(基因型)和81%(亚型)。核心关联方法在基因型水平上正确分类了所有HCV毒株,并在96%的病例中实现了适当的亚型分配。新设计的分型技术记录的这种分析性能特征优于所有市售检测方法报告的特征,包括最近发布的新一代线性探针检测。因此,HCV核心片段的CLIP测序以及随后类型和亚型的自动分配可以放心地用于临床实验室实践,以回答HCV分型方面的当前和未来问题。